{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:58:10Z","timestamp":1760237890617,"version":"build-2065373602"},"reference-count":62,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>There is a controversy about potentially positive or negative effects of caffeine consumption on onset and disease progression of neurodegenerative diseases such as Huntington\u2019s Disease (HD). On the molecular level, the psychoactive drug caffeine targets in particular adenosine receptors (AR) as a nonselective antagonist. The aim of this study was to evaluate clinical effects of caffeine consumption in patients suffering from premanifest and motor-manifest HD. Data of the global observational study ENROLL-HD were used, in order to analyze the course of HD regarding symptoms onset, motor, functional, cognitive and psychiatric parameters, using cross-sectional and longitudinal data of up to three years. We split premanifest and manifest participants into two subgroups: consumers of &gt;3 cups of caffeine (coffee, cola or black tea) per day (&gt;375 mL) vs. subjects without caffeine consumption. Data were analyzed using ANCOVA-analyses for cross-sectional and repeated measures analysis of variance for longitudinal parameters in IBM SPSS Statistics V.28. Within n = 21,045 participants, we identified n = 1901 premanifest and n = 4072 manifest HD patients consuming &gt;3 cups of caffeine\/day vs. n = 841 premanifest and n = 2243 manifest subjects without consumption. Manifest HD patients consuming &gt;3 cups exhibited a significantly better performance in a series of neuropsychological tests. They also showed at the median a later onset of symptoms (all p &lt; 0.001), and, during follow-up, less motor, functional and cognitive impairments in the majority of tests (all p &lt; 0.050). In contrast, there were no beneficial caffeine-related effects on neuropsychological performance in premanifest HD mutation carriers. They showed even worse cognitive performances in stroop color naming (SCNT) and stroop color reading (SWRT) tests (all p &lt; 0.050) and revealed more anxiety, depression and irritability subscores in comparison to premanifest participants without caffeine consumption. Similarly, higher self-reported anxiety and irritability were observed in genotype negative\/control group high dose caffeine drinkers, associated with a slightly better performance in some cognitive tasks (all p &lt; 0.050). The analysis of the impact of caffeine consumption in the largest real-world cohort of HD mutation carriers revealed beneficial effects on neuropsychological performance as well as manifestation and course of disease in manifest HD patients while premanifest HD mutation carrier showed no neuropsychological improvements, but worse cognitive performances in some tasks and exhibited more severe signs of psychiatric impairment. Our data point to state-related psychomotor-stimulant effects of caffeine in HD that might be related to regulatory effects at cerebral adenosine receptors. Further studies are required to validate findings, exclude potential other unknown biasing factors such as physical activity, pharmacological interventions, gender differences or chronic habitual influences and test for dosage related effects.<\/jats:p>","DOI":"10.3390\/biomedicines10061258","type":"journal-article","created":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T01:40:45Z","timestamp":1653702045000},"page":"1258","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Divergent Effects of the Nonselective Adenosine Receptor Antagonist Caffeine in Pre-Manifest and Motor-Manifest Huntington\u2019s Disease"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9950-7877","authenticated-orcid":false,"given":"Jannis","family":"Achenbach","sequence":"first","affiliation":[{"name":"Department of Neurology, Huntington Center North Rhine-Westphalia, St. Josef-Hospital Bochum, Ruhr-University Bochum, Gudrunstra\u00dfe 56, 44791 Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Matusch","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience and Medicine (INM-2), Forschungszentrum J\u00fclich, Wilhelm-Johnen-Stra\u00dfe, 52428 J\u00fclich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6137-416X","authenticated-orcid":false,"given":"David","family":"Elmenhorst","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience and Medicine (INM-2), Forschungszentrum J\u00fclich, Wilhelm-Johnen-Stra\u00dfe, 52428 J\u00fclich, Germany"},{"name":"Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50923 Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0117-3793","authenticated-orcid":false,"given":"Andreas","family":"Bauer","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience and Medicine (INM-2), Forschungszentrum J\u00fclich, Wilhelm-Johnen-Stra\u00dfe, 52428 J\u00fclich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Saft","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huntington Center North Rhine-Westphalia, St. Josef-Hospital Bochum, Ruhr-University Bochum, Gudrunstra\u00dfe 56, 44791 Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington\u2019s disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington\u2019s disease: From molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41582-020-0389-4","article-title":"Huntington disease: New insights into molecular pathogenesis and therapeutic opportunities","volume":"16","author":"Tabrizi","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Ellrichmann, G., Reick, C., Saft, C., and Linker, R.A. (2013). The role of the immune system in Huntington\u2019s disease. Clin. Dev. Immunol., 2013.","DOI":"10.1155\/2013\/541259"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Jimenez-Sanchez, M., Licitra, F., Underwood, B.R., and Rubinsztein, D.C. (2017). Huntington\u2019s Disease: Mechanisms of Pathogenesis and Therapeutic Strategies. Cold Spring Harb. Perspect. Med., 7.","DOI":"10.1101\/cshperspect.a024240"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40263-019-00695-3","article-title":"Recent Advances in the Treatment of Huntington\u2019s Disease: Targeting DNA and RNA","volume":"34","author":"Shannon","year":"2020","journal-title":"CNS Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/ajmg.a.38494","article-title":"Therapy development in Huntington disease: From current strategies to emerging opportunities","volume":"176","author":"Dickey","year":"2018","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/mds.27849","article-title":"One decade ago, one decade ahead in huntington\u2019s disease","volume":"34","author":"Wild","year":"2019","journal-title":"Mov. Disord."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","article-title":"Therapies targeting DNA and RNA in Huntington\u2019s disease","volume":"16","author":"Wild","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Achenbach, J., Saft, C., and Faissner, S. (2021). Longitudinal Evaluation of the Effect of Tricyclic Antidepressants and Neuroleptics on the Course of Huntington\u2019s Disease\u2014Data from a Real World Cohort. Brain Sci., 11.","DOI":"10.3390\/brainsci11040413"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/mds.23108","article-title":"A retrospective study of the impact of lifestyle on age at onset of Huntington disease","volume":"25","author":"Trembath","year":"2010","journal-title":"Mov. Disord."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Sathe, S., Ware, J., Levey, J., Neacy, E., Blumenstein, R., Noble, S., M\u00fchlb\u00e4ck, A., Rosser, A., Landwehrmeyer, G.B., and Sampaio, C. (2021). Enroll-HD: An Integrated Clinical Research Platform and Worldwide Observational Study for Huntington\u2019s Disease. Front. Neurol., 12.","DOI":"10.3389\/fneur.2021.667420"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/B978-0-12-801022-8.00012-X","article-title":"Adenosine receptor control of cognition in normal and disease","volume":"119","author":"Chen","year":"2014","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/cns.12684","article-title":"The neuroprotective effects of caffeine in neurodegenerative diseases","volume":"23","author":"Kolahdouzan","year":"2017","journal-title":"CNS Neurosci. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Ren, X., and Chen, J.-F. (2020). Caffeine and Parkinson\u2019s Disease: Multiple Benefits and Emerging Mechanisms. Front. Neurosci., 14.","DOI":"10.3389\/fnins.2020.602697"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/1533317508320083","article-title":"Caffeine: Neuroprotective functions in cognition and Alzheimer\u2019s disease","volume":"23","author":"Rosso","year":"2008","journal-title":"Am. J. Alzheimer\u2019s Dis. Other Demen."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1042\/BST20130229","article-title":"From epidemiology to pathophysiology: What about caffeine in Alzheimer\u2019s disease?","volume":"42","author":"Flaten","year":"2014","journal-title":"Biochem. Soc. Trans."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jsps.2020.02.005","article-title":"Caffeine induces neurobehavioral effects through modulating neurotransmitters","volume":"28","author":"Alasmari","year":"2020","journal-title":"Saudi Pharm. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.3233\/JAD-2010-1408","article-title":"Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline","volume":"20","author":"Cunha","year":"2010","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Soca\u0142a, K., Szopa, A., Serefko, A., Poleszak, E., and Wla\u017a, P. (2020). Neuroprotective Effects of Coffee Bioactive Compounds: A Review. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010107"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/fsn3.1078","article-title":"Green kiwifruit extracts protect motor neurons from death in a spinal muscular atrophy model in Caenorhabditis elegans","volume":"7","author":"Mazzarella","year":"2019","journal-title":"Food Sci. Nutr."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Pham, T.D. (2021). Recurrence eigenvalues of movements from brain signals. Brain Inform., 8.","DOI":"10.1186\/s40708-021-00143-3"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Cordeiro, L.M., Soares, M.V., Da Silva, A.F., Machado, M.L., Bicca Obetine Baptista, F., Da Silveira, T.L., Arantes, L.P., and Soares, F.A.A. (2021). Neuroprotective effects of rutin on ASH neurons in Caenorhabditis elegans model of Huntington\u2019s disease. Nutr. Neurosci., 1\u201314.","DOI":"10.1080\/1028415X.2021.1956254"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.14336\/AD.2021.0404","article-title":"Targeting Mitochondrial Network Disorganization is Protective in C. elegans Models of Huntington\u2019s Disease","volume":"12","author":"Machiela","year":"2021","journal-title":"Aging Dis."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Wang, Q., Zhang, J., Jiang, Y., Xiao, Y., Li, X., Mao, X., and Huang, Z. (2021). Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds against Polyglutamine-mediated Neurotoxicity. J. Vis. Exp., 175.","DOI":"10.3791\/63081-v"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Sutphin, G.L., Bishop, E., Yanos, M.E., Moller, R.M., and Kaeberlein, M. (2012). Caffeine extends life span, improves healthspan, and delays age-associated pathology in Caenorhabditis elegans. Longev. Healthspan, 1.","DOI":"10.1186\/2046-2395-1-9"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/ana.23866","article-title":"Caffeine and adenosine A(2A) receptor inactivation decrease striatal neuropathology in a lentiviral-based model of Machado-Joseph disease","volume":"73","author":"Cunha","year":"2013","journal-title":"Ann. Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/B978-0-12-801022-8.00010-6","article-title":"Adenosine receptors and Huntington\u2019s disease","volume":"119","author":"Lee","year":"2014","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Fredholm, B.B., Chen, J.-F., Cunha, R.A., Svenningsson, P., and Vaugeois, J.-M. (2005). Adenosine and Brain Function, Elsevier.","DOI":"10.1016\/S0074-7742(05)63007-3"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bcp.2019.06.008","article-title":"The physiological effects of caffeine on synaptic transmission and plasticity in the mouse hippocampus selectively depend on adenosine A1 and A2A receptors","volume":"166","author":"Lopes","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/caff.2018.0006","article-title":"The Role of Adenosine Tone and Adenosine Receptors in Huntington\u2019s Disease","volume":"8","author":"Blum","year":"2018","journal-title":"J. Caffeine Adenosine Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.nbd.2009.06.009","article-title":"A genetic variation in the ADORA2A gene modifies age at onset in Huntington\u2019s disease","volume":"35","author":"Dhaenens","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10048-010-0248-3","article-title":"Age at onset in Huntington\u2019s disease: Replication study on the associations of ADORA2A, HAP1 and OGG1","volume":"11","author":"Saft","year":"2010","journal-title":"Neurogenetics"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Mishina, M., Ishii, K., Kimura, Y., Suzuki, M., Kitamura, S., Ishibashi, K., Sakata, M., Oda, K., Kobayashi, S., and Kimura, K. (2017). Adenosine A1 receptors measured with 11 C-MPDX PET in early Parkinson\u2019s disease. Synapse, 71.","DOI":"10.1002\/syn.21979"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1007\/s00259-020-05164-4","article-title":"Improved in vivo PET imaging of the adenosine A2A receptor in the brain using 18FFLUDA, a deuterated radiotracer with high metabolic stability","volume":"48","author":"Lai","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1007\/s00259-014-2724-8","article-title":"Cross sectional PET study of cerebral adenosine A\u2081 receptors in premanifest and manifest Huntington\u2019s disease","volume":"41","author":"Matusch","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.pharep.2014.07.006","article-title":"Improvement of mitochondrial NAD(+)\/FAD(+)-linked state-3 respiration by caffeine attenuates quinolinic acid induced motor impairment in rats: Implications in Huntington\u2019s disease","volume":"66","author":"Mishra","year":"2014","journal-title":"Pharmacol. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.1016\/j.clnu.2021.09.041","article-title":"Mendelian randomization study of coffee consumption and age at onset of Huntington\u2019s disease","volume":"40","author":"Wang","year":"2021","journal-title":"Clin. Nutr."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.nbd.2013.05.013","article-title":"Association between caffeine intake and age at onset in Huntington\u2019s disease","volume":"58","author":"Simonin","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/mds.27239","article-title":"Selected health and lifestyle factors, cytosine-adenine-guanine status, and phenoconversion in Huntington\u2019s disease","volume":"33","author":"Tanner","year":"2018","journal-title":"Mov. Disord."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.parkreldis.2021.05.012","article-title":"Data from ENROLL-HD: Is the prevalence of juvenile and pediatric Huntington\u2019s disease overestimated?","volume":"88","author":"Achenbach","year":"2021","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ajmg.b.31232","article-title":"Indexing disease progression at study entry with individuals at-risk for Huntington disease","volume":"156","author":"Zhang","year":"2011","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ajmg.b.30992","article-title":"CAG-repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches","volume":"153","author":"Langbehn","year":"2010","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.29.1.1","article-title":"Huntington disease: Clinical care and evaluation","volume":"29","author":"Shoulson","year":"1979","journal-title":"Neurology"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"(1996). Unified Huntington\u2019s Disease Rating Scale: Reliability and consistency. Huntington Study Group. Mov. Disord., 11, 136\u2013142.","DOI":"10.1002\/mds.870110204"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Baur, D.M., Lange, D., Elmenhorst, E.-M., Elmenhorst, D., Bauer, A., Aeschbach, D., and Landolt, H.-P. (2021). Coffee effectively attenuates impaired attention in ADORA2A C\/C-allele carriers during chronic sleep restriction. Prog. Neuropsychopharmacol. Biol. Psychiatry, 109.","DOI":"10.1016\/j.pnpbp.2020.110232"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2967\/jnumed.112.105114","article-title":"Caffeine occupancy of human cerebral A1 adenosine receptors: In vivo quantification with 18F-CPFPX and PET","volume":"53","author":"Elmenhorst","year":"2012","journal-title":"J. Nucl. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.nbd.2015.03.030","article-title":"Inactivation of adenosine A2A receptors reverses working memory deficits at early stages of Huntington\u2019s disease models","volume":"79","author":"Li","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1093\/hmg\/ddp230","article-title":"The A2A adenosine receptor rescues the urea cycle deficiency of Huntington\u2019s disease by enhancing the activity of the ubiquitin-proteasome system","volume":"18","author":"Chiang","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/B978-0-12-801893-4.00012-2","article-title":"Medical management of motor manifestations of Huntington disease","volume":"144","author":"McCusker","year":"2017","journal-title":"Handb. Clin. Neurol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1385\/JMN:26:2-3:209","article-title":"Adenosine A2A and Dopamine D2 Heteromeric Receptor Complexes and Their Function","volume":"26","author":"Fuxe","year":"2005","journal-title":"JMN"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/0004867415603131","article-title":"Coffee and caffeine consumption and depression: A meta-analysis of observational studies","volume":"50","author":"Wang","year":"2016","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"7833","DOI":"10.1073\/pnas.1423088112","article-title":"Caffeine acts through neuronal adenosine A2A receptors to prevent mood and memory dysfunction triggered by chronic stress","volume":"112","author":"Kaster","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1038\/s41380-021-01075-4","article-title":"Habitual coffee drinkers display a distinct pattern of brain functional connectivity","volume":"26","author":"Esteves","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"147","DOI":"10.31887\/DCNS.2017.19.2\/dnutt","article-title":"Biological markers of generalized anxiety disorder","volume":"19","author":"Maron","year":"2017","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Jee, H.J., Lee, S.G., Bormate, K.J., and Jung, Y.-S. (2020). Effect of Caffeine Consumption on the Risk for Neurological and Psychiatric Disorders: Sex Differences in Human. Nutrients, 12.","DOI":"10.3390\/nu12103080"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nbd.2014.11.004","article-title":"Hyperactivation of D1 and A2A receptors contributes to cognitive dysfunction in Huntington\u2019s disease","volume":"74","author":"Tyebji","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/jnc.13724","article-title":"How does adenosine control neuronal dysfunction and neurodegeneration?","volume":"139","author":"Cunha","year":"2016","journal-title":"J. Neurochem."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Watson, E.J., Coates, A.M., Kohler, M., and Banks, S. (2016). Caffeine Consumption and Sleep Quality in Australian Adults. Nutrients, 8.","DOI":"10.3390\/nu8080479"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1212\/WNL.55.9.1350","article-title":"Smoking, alcohol, and coffee consumption preceding Parkinson\u2019s disease: A case-control study","volume":"55","author":"Benedetti","year":"2000","journal-title":"Neurology"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Cornelis, M.C., and Munafo, M.R. (2018). Mendelian Randomization Studies of Coffee and Caffeine Consumption. Nutrients, 10.","DOI":"10.3390\/nu10101343"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2147\/RMHP.S156404","article-title":"Effects of caffeine on sleep quality and daytime functioning","volume":"11","author":"Muurlink","year":"2018","journal-title":"Risk Manag. Healthc. Policy"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/6\/1258\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:19:58Z","timestamp":1760138398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/6\/1258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,27]]},"references-count":62,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["biomedicines10061258"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10061258","relation":{},"ISSN":["2227-9059"],"issn-type":[{"type":"electronic","value":"2227-9059"}],"subject":[],"published":{"date-parts":[[2022,5,27]]}}}